MCID: THR100
MIFTS: 57

Thrombocytopenic Purpura, Autoimmune

Categories: Rare diseases, Immune diseases, Blood diseases

Aliases & Classifications for Thrombocytopenic Purpura, Autoimmune

MalaCards integrated aliases for Thrombocytopenic Purpura, Autoimmune:

Name: Thrombocytopenic Purpura, Autoimmune 53 72 55 13
Idiopathic Thrombocytopenic Purpura 53 12 72 49
Immune Thrombocytopenic Purpura 53 12 55 69
Autoimmune Thrombocytopenic Purpura 12 49 14
Itp 53 49 55
Thrombocytopenia Due to Platelet Alloimmunization 69
Purpura, Thrombocytopenic, Idiopathic 41
Immune Thrombocytopenic Purpura; Itp 53
Thrombocytopenic Purpura Autoimmune 49
Purpura Thrombocytopenic Idiopathic 51
Primary Thrombocytopenic Purpura 12
Ideopath Thrombocytopenic Pur 12
Autoimmune Thrombocytopenia 69
Immune Thrombocytopenia 55
Idiopathic Purpura 12
Werlhof's Disease 12
Aitp 53

Characteristics:

Orphanet epidemiological data:

55
immune thrombocytopenic purpura
Inheritance: Not applicable; Prevalence: 1-5/10000 (Europe),1-9/100000 (France); Age of onset: All ages;

OMIM:

53
Inheritance:
autosomal dominant form


HPO:

31
thrombocytopenic purpura, autoimmune:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

OMIM 53 188030
Disease Ontology 12 DOID:8924
ICD10 32 D69.3
ICD9CM 34 287.31
MeSH 41 D016553
NCIt 46 C3446
Orphanet 55 ORPHA3002
MESH via Orphanet 42 D016553
UMLS via Orphanet 70 C0398650
ICD10 via Orphanet 33 D69.3
MedGen 39 C0398650

Summaries for Thrombocytopenic Purpura, Autoimmune

NIH Rare Diseases : 49 Idiopathic thrombocytopenic purpura (ITP) is a bleeding disorder characterized by too few platelets in the blood. This is because platelets are being destroyed by the immune system. Symptoms may include bruising, nosebleed or bleeding in the mouth, bleeding into the skin, and abnormally heavy menstruation. With treatment, the chance of remission (a symptom-free period) is good. Rarely, ITP may become a chronic ailment in adults and reappear, even after remission. Last updated: 6/6/2016

MalaCards based summary : Thrombocytopenic Purpura, Autoimmune, also known as idiopathic thrombocytopenic purpura, is related to thrombocytopenia due to platelet alloimmunization and purpura, and has symptoms including thrombocytopenia, thromboembolism and petechiae. An important gene associated with Thrombocytopenic Purpura, Autoimmune is FCGR2C (Fc Fragment Of IgG Receptor IIc (Gene/Pseudogene)), and among its related pathways/superpathways are TGF-Beta Pathway and Response to elevated platelet cytosolic Ca2+. The drugs Dexamethasone and Amodiaquine have been mentioned in the context of this disorder. Affiliated tissues include lung, heart and prostate, and related phenotypes are hematopoietic system and immune system

OMIM : 53 Autoimmune thrombocytopenic purpura is characterized by a low platelet count, normal bone marrow, and the absence of other causes of thrombocytopenia. It is principally a disorder of increased platelet destruction mediated by autoantibodies to platelet-membrane antigens (George et al., 1994). (188030)

Disease Ontology : 12 A primary thrombocytopenia that involves relatively few platelets in blood as a result of autoantibodies.

Wikipedia : 72 Immune thrombocytopenia (ITP) is a type of thrombocytopenic purpura defined as isolated low platelet... more...

Related Diseases for Thrombocytopenic Purpura, Autoimmune

Diseases related to Thrombocytopenic Purpura, Autoimmune via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 57)
# Related Disease Score Top Affiliating Genes
1 thrombocytopenia due to platelet alloimmunization 30.9 FCGR2C ITGA2B MPL SELP THPO
2 purpura 29.4 GP1BA ITGA2B ITGB3 MPL THPO
3 sea-blue histiocyte disease 11.5
4 immunodeficiency, common variable, 8, with autoimmunity 11.4
5 thrombotic thrombocytopenic purpura, acquired 11.3
6 thrombocytopenia 3 10.4 MPL THPO
7 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.4
8 thrombocythemia 1 10.4 MPL THPO
9 dyskeratosis congenita, autosomal dominant 6 10.4 MPL THPO
10 amegakaryocytic thrombocytopenia, congenital 10.4 MPL THPO
11 splenomegaly 10.2 IFNA2 MPL
12 thrombocytopenia-absent radius syndrome 10.2 GP1BA MPL THPO
13 sticky platelet syndrome 10.2 GP6 ITGB3
14 acquired thrombocytopenia 10.2 IL11 THPO
15 sarcomatoid renal cell carcinoma 10.1 GATA3 IFNA2
16 anemia, autoimmune hemolytic 10.1
17 arteritic anterior ischemic optic neuropathy 10.1 GP1BA ITGB3
18 clopidogrel resistance 10.1 ITGB3 SELP
19 leukemia, chronic myeloid 10.1 IFNA2 MPL THPO
20 hemolytic anemia 10.0
21 myelofibrosis 10.0 IFNA2 MPL THPO
22 coronary thrombosis 10.0 GP1BA GP6 ITGB3
23 thrombotic thrombocytopenic purpura 10.0
24 bleeding disorder, platelet-type, 16 9.9 ITGA2B ITGB3
25 exanthema subitum 9.9 ITGA2B THPO
26 infective endocarditis 9.9 GP1BA ITGB3
27 polycythemia vera 9.8 ITGB3 MPL SELP THPO
28 carotid artery thrombosis 9.8 ITGA2B SELP
29 malignant skin fibrous histiocytoma 9.8 IFNA2 ITGA2B
30 eosinophilic fasciitis 9.8
31 myasthenia gravis 9.8
32 gastric cancer 9.8
33 evans' syndrome 9.8
34 fasciitis 9.8
35 myasthenia gravis congenital 9.8
36 leukocyte adhesion deficiency, type iii 9.8 ITGA2B SELP
37 fetal and neonatal alloimmune thrombocytopenia 9.8 GP1BA ITGA2B ITGB3
38 autosomal dominant macrothrombocytopenia 9.8 GP1BA ITGA2B ITGB3
39 inherited blood coagulation disease 9.8 GP1BA ITGA2B ITGB3
40 intermediate coronary syndrome 9.7 ITGA2B SELP
41 malignant dermis tumor 9.7 IFNA2 ITGA2B
42 myelodysplastic syndrome 9.7 DNMT3B IL11 MPL THPO
43 thrombocytosis 9.7 IL11 MPL SELP THPO
44 granulomatous hepatitis 9.6 IFNA2 ITGA2B
45 autoimmune disease of blood 9.6 ITGA2B ITGB3 MPL THPO
46 megakaryocytic leukemia 9.6 IL11 ITGA2B THPO
47 bernard-soulier syndrome 9.6 GP1BA ITGA2B ITGB3 THPO
48 thrombasthenia 9.4 GP1BA ITGA2B ITGB3 SELP
49 glanzmann thrombasthenia 9.4 GP1BA ITGA2B ITGB3 SELP
50 blood coagulation disease 9.4 GP1BA ITGA2B ITGB3 MPL THPO

Graphical network of the top 20 diseases related to Thrombocytopenic Purpura, Autoimmune:



Diseases related to Thrombocytopenic Purpura, Autoimmune

Symptoms & Phenotypes for Thrombocytopenic Purpura, Autoimmune

Symptoms via clinical synopsis from OMIM:

53
Heme:
thrombocytopenia
bleeding diathesis

Lab:
platelet antibody


Clinical features from OMIM:

188030

Human phenotypes related to Thrombocytopenic Purpura, Autoimmune:

55 31 (show all 12)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 thrombocytopenia 55 31 hallmark (90%) Very frequent (99-80%) HP:0001873
2 thromboembolism 55 31 hallmark (90%) Very frequent (99-80%) HP:0001907
3 petechiae 55 31 frequent (33%) Frequent (79-30%) HP:0000967
4 arterial thrombosis 55 31 frequent (33%) Frequent (79-30%) HP:0004420
5 gingival bleeding 55 31 occasional (7.5%) Occasional (29-5%) HP:0000225
6 epistaxis 55 31 occasional (7.5%) Occasional (29-5%) HP:0000421
7 bruising susceptibility 55 31 occasional (7.5%) Occasional (29-5%) HP:0000978
8 gastrointestinal hemorrhage 55 31 occasional (7.5%) Occasional (29-5%) HP:0002239
9 cerebral hemorrhage 55 31 very rare (1%) Very rare (<4-1%) HP:0001342
10 purpura 55 Frequent (79-30%)
11 abnormal bleeding 31 HP:0001892
12 platelet antibody positive 31 HP:0003454

MGI Mouse Phenotypes related to Thrombocytopenic Purpura, Autoimmune:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.65 DNMT3B GATA3 GP1BA GP6 ITGA2B ITGB3
2 immune system MP:0005387 9.28 DNMT3B GATA3 GP6 ITGA2B ITGB3 LRBA

Drugs & Therapeutics for Thrombocytopenic Purpura, Autoimmune

Drugs for Thrombocytopenic Purpura, Autoimmune (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 932)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 50-02-2 5743
2
Amodiaquine Approved, Investigational Phase 4 86-42-0 2165
3
Artemether Approved Phase 4,Phase 3 71963-77-4 68911 119380
4
Artesunate Approved, Investigational Phase 4 88495-63-0 5464098 6917864
5
Lumefantrine Approved Phase 4,Phase 3 82186-77-4 6437380
6
Mefloquine Approved, Investigational Phase 4 53230-10-7 4046
7
Alfentanil Approved, Illicit Phase 4 71195-58-9 51263
8
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 83-43-2 6741
9
Prednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 50-24-8 5755
10
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 2 50-28-2 5757
11
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
12
Moxifloxacin Approved, Investigational Phase 4 151096-09-2, 354812-41-2 152946
13
Norgestimate Approved, Investigational Phase 4 35189-28-7 6540478
14
Pyrimethamine Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 58-14-0 4993
15
Sulfadoxine Approved, Investigational Phase 4,Phase 3,Phase 2 2447-57-6 17134
16
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 3 148553-50-8 5486971
17
Valproic Acid Approved, Investigational Phase 4 99-66-1 3121
18
Amoxicillin Approved, Vet_approved Phase 4,Phase 2,Phase 3 26787-78-0 33613 2171
19
Clarithromycin Approved Phase 4,Phase 2,Phase 3,Phase 1 81103-11-9 84029
20
Dexlansoprazole Approved, Investigational Phase 4,Phase 2 138530-94-6, 103577-45-3 9578005
21
Lansoprazole Approved, Investigational Phase 4,Phase 2 103577-45-3 3883
22
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 174722-31-7 10201696
23
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 53-03-2 5865
24
Zinc Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 7440-66-6 32051 23994
25
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1 159351-69-6 6442177
26
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
27
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 53123-88-9 46835353 6436030 5284616
28
Adalimumab Approved Phase 4,Phase 3 331731-18-1 16219006
29
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2 2068-78-2, 57-22-7 5978
30
Dinoprostone Approved Phase 4 363-24-6 5280360
31
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
32
Nepafenac Approved, Investigational Phase 4 78281-72-8 151075
33
Ezetimibe Approved Phase 4 163222-33-1 150311
34
Simvastatin Approved Phase 4,Phase 3,Phase 1,Phase 2 79902-63-9 54454
35
Citalopram Approved Phase 4,Phase 3,Phase 2 59729-33-8 2771
36
Lopinavir Approved Phase 4 192725-17-0 92727
37
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
38
Acetaminophen Approved Phase 4,Phase 3 103-90-2 1983
39
Pioglitazone Approved, Investigational Phase 4,Phase 2 111025-46-8 4829
40
Rosiglitazone Approved, Investigational Phase 4,Phase 1 122320-73-4 77999
41
Heparin Approved, Investigational Phase 4,Phase 3 9005-49-6 46507594 772
42
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
43
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
44
Yohimbine Approved, Investigational, Vet_approved Phase 4 146-48-5 8969
45
Imipramine Approved Phase 4 50-49-7 3696
46
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 216974-75-3
47
Ranibizumab Approved Phase 4,Phase 3,Phase 2 347396-82-1 459903
48
Desipramine Approved, Investigational Phase 4,Phase 2,Phase 1 50-47-5 2995
49
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-61-6, 62-31-7 681
50
Methamphetamine Approved, Illicit Phase 4,Phase 2,Phase 1 537-46-2 10836

Interventional clinical trials:

(show top 50) (show all 1431)

# Name Status NCT ID Phase Drugs
1 Caffeic Acid Combining High-dose Dexamethasone in Management of ITP Unknown status NCT02556814 Phase 4 Caffeic acid tablets;Dexamethasone;placebo
2 Effectiveness of Artemisinin Combination Regimens in Falciparum Malaria Unknown status NCT00902811 Phase 4 AM(FDC);AM(LT);AL;DP;AA(FDC)
3 Pain Evaluation During Follicle Aspiration: Comparison of Two Sedation Protocols Unknown status NCT00742807 Phase 4 Low dose of alfentanil hydrochloride;Normal dose of alfentanil hydrochloride
4 Comparison of a Nutritional Anti-Inflammatory Treatment to Steroids for Pediatric Crohn's Disease - the Molecular Basis Unknown status NCT00265772 Phase 4 MODULEN IBD (R) (specific Enteral Nutrition);prednisolon
5 A Comparison of Prophylactic Antibacterial Efficacy of Besivance vs. VIGAMOX Prior to Cataract Surgery Unknown status NCT01296542 Phase 4
6 Aqueous Absorption and Pharmacokinetics of Besivance Versus VIGAMOX in Patients Undergoing Phacoemulsification Unknown status NCT01296191 Phase 4 Moxifloxacin;besifloxacin
7 Graz Study on the Risk of Atrial Fibrillation Unknown status NCT01461434 Phase 4
8 Efficacy and Safety of rHuTPO on Platelet Engraftment After Allo-HSCT Unknown status NCT01379391 Phase 4 Recombinant Human Thrombopoietin (rHTPO)
9 tDCS as Add on Therapy for Treatment of Tobacco Dependence by Standardized Behaviour Therapy Unknown status NCT01729507 Phase 4
10 Intermittent Antimalaria Treatment With SP in African Children Unknown status NCT00168948 Phase 4 Sulfadoxin (12.5) Pyrimethamine (250 mg)
11 Efficacy and Safety of Amodiaquine and Amodiaquine-Artesunate Unknown status NCT00238017 Phase 4 amodiaquine-artesunate versus amodiaquine
12 Using Non-Fluoroscopic Imaging Devices to Decrease Radiation Exposure During Ablation of Supraventricular Tachycardia Unknown status NCT00979303 Phase 4
13 Effects of Pregabalin on Mechanical Hyperalgesia Unknown status NCT00310583 Phase 4 Pregabalin
14 Pharmacogenomics of Mood Stabilizer Response in Bipolar Disorder (PGBD) Unknown status NCT01272531 Phase 4 Mood stabilizer treatment
15 Helicobacter Pylori Infection in Children With Chronic Idiopathic Thrombocytopenic Purpura Completed NCT00467571 Phase 4 lansoprazole, clarithromycin, amoxycillin
16 A Safety Study of Intravenous Immunoglobulin in Patients With Chronic Immune Thrombocytopenic Purpura (ITP) Completed NCT01390649 Phase 4
17 Platelet Function in Idiopathic Thrombocytopenic Purpura (ITP) Patients With Eltrombopag Completed NCT00888901 Phase 4 eltrombopag;corticosteroids (Aprednislon)
18 The Study of Different Dose Rituximab in the Treatment of ITP Completed NCT03258866 Phase 4 Rituximab;Rituximab
19 Study on Bone Marrow Morphology in Adults Receiving Romiplostim for Treatment of Thrombocytopenia Associated With Immune Thrombocytopenia Purpura (ITP) Completed NCT00907478 Phase 4
20 High-dose Dexamethasone Versus Conventional Dose Prednisone for Initial Treatment of Primary Immune Thrombocytopenia (ITP) Completed NCT01356511 Phase 4 Prednisone;Dexamethasone
21 A Comparison of Prostaglandin E2 (PGE2) Inhibition of Acuvail(Ketorolac 0.45%), Xibrom (Bromfenac 0.09%)and Nevanac (Nepafenac)in Patients Undergoing Phacoemulsification Completed NCT01021761 Phase 4 Ketorolac Tromethamine;Bromfenac;nepafenac
22 A Comparison of Peak Aqueous Penetration of Acuvail (Ketorolac 0.45%), Xibrom (Bromfenac 0.09%), and Nevanac (Nepafenac 0.1%)in Patients Undergoing Phacoemulsification Completed NCT01001806 Phase 4 Ketorolac Tromethamine 0.45%;bromfenac 0.09%;nepafenac 0.1%
23 The PostprAndial eNdothelial Function After Combination of Ezetimibe and simvAstatin Study Completed NCT00817843 Phase 4 Simvastatin;Simvastatin/Ezetimibe
24 Comparison of Rotating vs. Fixed Platform of the COLUMBUS Knee Prosthesis Completed NCT00822640 Phase 4
25 Treatment of Depression in Adults Completed NCT00073697 Phase 4 Escitalopram
26 Raltegravir Kaletra Pharmacokinetics Completed NCT00564772 Phase 4 Raltegravir, lopinavir, ritonavir
27 Aqueous Concentrations and PGE2 Inhibition of Ketorolac 0.4% vs. Bromfenac 0.09% in Cataract Patients: Trough Drug Effects Completed NCT00469690 Phase 4 Acular, Xibrom
28 Paracetamol and Endothelial Function in Patients With Stable Coronary Artery Disease Completed NCT00534651 Phase 4 Paracetamol
29 A Comparison of Post Phacoemulsification Aqueous Flare in Patients Using Ketorolac 0.45% 2 Times Daily (BID) and Bromfenac 0.09% 2 Times Daily (BID) Completed NCT01023724 Phase 4 Ketorolac Tromethamine 0.45%;Bromfenac 0.09%
30 Effect of Thiazolidinedione Treatment Vascular Risk Markers Completed NCT00571506 Phase 4 Rosiglitazone;Pioglitazone
31 Mechanism of Fatty Acid-induced Impairment of Glucose-simulated Insulin Secretion - Effect of Buphenyl Completed NCT00533559 Phase 4 sodium phenylbutyrate;Placebo
32 Mechanism of Fatty Acid-Induced Impairment of Glucose-Stimulated Insulin Secretion Completed NCT00188773 Phase 4 N-acetylcysteine, intralipid, heparin
33 Moxifloxacin vs. Polytrim for Conjunctivitis Completed NCT00581542 Phase 4 moxifloxacin;polytrim
34 Mechanism of Growth Hormone Effects on Adipose Tissue Completed NCT00453557 Phase 4 rhGH
35 "TAKE TIME" Pioglitazone Reverses Defects in Mitochondrial Biogenesis in Patients With T2DM Completed NCT00402012 Phase 4 Pioglitazone
36 Aqueous Concentrations and PGE2 Inhibition of Ketorolac 0.4% vs. Bromfenac 0.09% in Cataract Patients Completed NCT00347503 Phase 4 ketorolac 0.4%, bromfenac 0.09%
37 Effects of Comorbid Personality Disorder on the Treatment of Bipolar I Disorder Completed NCT00178061 Phase 4
38 Oat Breakfast Satiety Study Completed NCT01372683 Phase 4
39 Bioequivalence Study Comparing Two Test Products With One Reference Product, All Containing 5 mg Yohimbine Completed NCT00975325 Phase 4 Yohimbine;Yohimbine
40 Miralax (PEG 3350) vs. Golytely as Bowel Preparation for Screening Colonoscopy Completed NCT01170754 Phase 4 PEG-3350 and Gatorade;Golytely 4 liters
41 Psychosocial Therapy Plus Maintenance Pharmacotherapy for Treating Bipolar Disorder Completed NCT00227968 Phase 4
42 Comparing Various Treatments for Achieving and Maintaining Remission of Depression Completed NCT00227955 Phase 4 Imipramine
43 Pharmacokinetic Study of Topically Applied Veregen 15% Compared With Oral Intake of Green Tea Beverage Completed NCT01082302 Phase 4 Polyphenon E (Veregen) 15% ointment
44 Xpert MTB/Rif, a New Tool for the Diagnosis of Pulmonary Tuberculosis in Two Municipalities in Brazil Completed NCT01363765 Phase 4
45 VEGF-antagonism and Endothelial Function in Age-related Macular Degeneration (AMD) Completed NCT00727753 Phase 4 Ranibizumab;Bevacizumab
46 Is Omega-3 Fatty Acid Red Blood Cell (RBC) Saturation Product Dependent? Completed NCT01091714 Phase 4
47 Standard Open Surgery Versus Endovascular Repair of Abdominal Aortic Aneurysm (AAA) Completed NCT00094575 Phase 4
48 Effects of Ezetimibe on Postprandial Hyperlipidemia and Endothelial Function Completed NCT00189085 Phase 4 simvastatin and ezetimibe
49 Depression: The Search for Treatment-Relevant Phenotypes-Pilot Study Completed NCT00222820 Phase 4 escitalopram
50 Methamphetamine Abuse Treatment in Patients With AIDS - 1 Completed NCT00000321 Phase 4 Desipramine

Search NIH Clinical Center for Thrombocytopenic Purpura, Autoimmune

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: purpura, thrombocytopenic, idiopathic

Genetic Tests for Thrombocytopenic Purpura, Autoimmune

Anatomical Context for Thrombocytopenic Purpura, Autoimmune

MalaCards organs/tissues related to Thrombocytopenic Purpura, Autoimmune:

38
Lung, Heart, Prostate, Bone, Kidney, Testes, Brain

Publications for Thrombocytopenic Purpura, Autoimmune

Articles related to Thrombocytopenic Purpura, Autoimmune:

# Title Authors Year
1
Autoimmune thrombocytopenic purpura, autoimmune hemolytic anemia and gastric cancer appeared in a patient with myasthenia gravis. ( 16679706 )
2006
2
Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome. ( 14601692 )
2003
3
Eosinophilic fasciitis following idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia and Hashimoto's disease. ( 10592421 )
1999

Variations for Thrombocytopenic Purpura, Autoimmune

Copy number variations for Thrombocytopenic Purpura, Autoimmune from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 21699 1 160500000 165500000 Copy number FCGR2C Idiopathic thrombocytopenic purpura
2 46119 10 77700000 82000000 Copy number BMPR1A Idiopathic thrombocytopenic purpura
3 121460 18 43500000 48200000 Copy number MADH4 Idiopathic thrombocytopenic purpura

Expression for Thrombocytopenic Purpura, Autoimmune

Search GEO for disease gene expression data for Thrombocytopenic Purpura, Autoimmune.

Pathways for Thrombocytopenic Purpura, Autoimmune

Pathways related to Thrombocytopenic Purpura, Autoimmune according to GeneCards Suite gene sharing:

(show all 15)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.26 IFNA2 IL11 ITGA2B ITGB3 MPL THPO
2
Show member pathways
12.69 GATA3 GP1BA GP6 IFNA2 ITGA2B ITGB3
3
Show member pathways
12.09 IFNA2 IL11 MPL THPO
4
Show member pathways
11.94 GP6 ITGB3 SELP
5
Show member pathways
11.85 GP1BA GP6 ITGA2B ITGB3
6 11.71 GP1BA GP6 ITGA2B ITGB3
7
Show member pathways
11.65 GP1BA ITGA2B ITGB3 MPL THPO
8 11.54 GP1BA IL11 ITGA2B ITGB3 THPO
9 11.32 GP6 ITGA2B ITGB3
10 11.23 GP1BA IFNA2 IL11 ITGA2B ITGB3 MPL
11 11.06 ITGA2B ITGB3
12 10.93 ITGA2B ITGB3
13 10.8 ITGA2B ITGB3
14 10.74 IL11 ITGA2B ITGB3 THPO
15 10.57 GP1BA GP6

GO Terms for Thrombocytopenic Purpura, Autoimmune

Cellular components related to Thrombocytopenic Purpura, Autoimmune according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.63 GP1BA GP6 ITGA2B ITGB3 MPL SELP
2 cell surface GO:0009986 9.35 GP1BA GP6 ITGA2B ITGB3 MPL
3 integrin complex GO:0008305 9.26 ITGA2B ITGB3
4 platelet alpha granule membrane GO:0031092 8.8 ITGA2B ITGB3 SELP

Biological processes related to Thrombocytopenic Purpura, Autoimmune according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 leukocyte migration GO:0050900 9.61 GP6 ITGB3 SELP
2 cytokine-mediated signaling pathway GO:0019221 9.54 GP1BA IFNA2 MPL
3 platelet degranulation GO:0002576 9.5 ITGA2B ITGB3 SELP
4 platelet activation GO:0030168 9.43 GP1BA GP6 ITGB3
5 negative regulation of endothelial cell apoptotic process GO:2000352 9.4 GATA3 IL11
6 positive regulation of leukocyte migration GO:0002687 9.16 ITGA2B SELP
7 blood coagulation GO:0007596 9.02 GATA3 GP1BA GP6 IFNA2 ITGB3
8 thrombopoietin-mediated signaling pathway GO:0038163 8.96 MPL THPO

Molecular functions related to Thrombocytopenic Purpura, Autoimmune according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.13 IFNA2 IL11 THPO
2 extracellular matrix binding GO:0050840 8.62 ITGA2B ITGB3

Sources for Thrombocytopenic Purpura, Autoimmune

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....